文献速递浆细胞疾病造血干细胞移植与细胞治疗

Talquetamab联合达雷妥尤单抗治疗复发或难治性多发性骨髓瘤:TRIMM-2研究

Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study.
PubMed 文献 · Blood · 2025-01-01

TRIMM-2为1b期研究,65例复发/难治性多发性骨髓瘤患者接受皮下talquetamab(每周0.4 mg/kg或每两周0.8 mg/kg)联合达雷妥尤单抗1800 mg治疗,主要终点为安全性。最常见不良事件为口腔事件、皮肤事件、细胞因子释放综合征和感染,3/4级事件占81.5%;总缓解率分别为71.4%(每周组)和82.4%(每两周组),中位无进展生存期分别为23.3和21.2个月。

要点

  • TRIMM-2研究纳入65例重度经治复发/难治性多发性骨髓瘤患者,接受talquetamab联合达雷妥尤单抗治疗。
  • 3/4级不良事件发生率为81.5%,最常见不良事件为口腔事件、皮肤事件、细胞因子释放综合征和感染。
  • 每周组与每两周组总缓解率分别为71.4%和82.4%,中位无进展生存期分别为23.3和21.2个月。

核心结论

  • Talquetamab联合达雷妥尤单抗在重度经治的复发/难治性多发性骨髓瘤患者中显示出有前景的疗效,安全性特征与各单药一致。

研究设计与样本

  • 1b期TRIMM-2研究纳入65例复发/难治性多发性骨髓瘤患者(既往至少3线治疗或对蛋白酶体抑制剂和免疫调节药物双重难治),接受皮下talquetamab 0.4 mg/kg每周(每周组,n=14)或0.8 mg/kg每两周(每两周组,n=51)联合达雷妥尤单抗1800 mg按获批方案给药。
  • 主要终点为安全性,次要终点包括总缓解率和缓解持续时间,无进展生存期为探索性终点。
  • 患者中位既往治疗线数为5,三重难治者占61.5%,双特异性抗体经治者占24.6%,中位随访18.6个月。

主要发现

  • 最常见不良事件为口腔事件、皮肤事件、细胞因子释放综合征和感染,3级或4级事件发生于81.5%的患者。
  • 两例患者出现剂量限制性毒性,均位于每两周组(3级口腔炎/口腔黏膜炎和3级斑丘疹)。
  • 总缓解率在每周组为71.4%,在每两周组为82.4%。
  • 中位无进展生存期在每周组为23.3个月,在每两周组为21.2个月。
  • 药效学结果提示达雷妥尤单抗的免疫调节作用通过减少免疫抑制细胞为talquetamab创造有利环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Talquetamab, a G protein-coupled receptor class C group 5 member D-targeting bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), plus daratumumab, may lead to deeper and more durable responses than either therapy alone. In the phase 1b TRIMM-2 study, patients with R/R MM (at least 3 previous lines of therapy or double refractory to a proteasome inhibitor and an immunomodulatory drug) received subcutaneous talquetamab 0.4 mg/kg weekly (QW; "QW cohort") or 0.8 mg/kg every other week (Q2W cohort) plus daratumumab 1800 mg per the approved schedule. The primary end point was safety. Secondary end points included overall response and duration of response. Progression-free survival was an exploratory end point. Sixty-five patients (median 5 previous lines of therapy; 61.5% triple-class refractory; 24.6% bispecific antibody exposed) received talquetamab plus daratumumab (QW, n = 14; Q2W, n = 51; median follow-up of 18.6 months). Most common adverse events were oral events, skin events, cytokine release syndrome, and infections. Grade 3 or 4 events occurred in 81.5%. Two patients had dose-limiting toxicities, both in the Q2W cohort (grade 3 stomatitis/oral mucositis, and grade 3 maculopapular rash). Responses occurred in 71.4% (QW cohort) and 82.4% (Q2W cohort) of patients. Median progression-free survival was 23.3 and 21.2 months, respectively, in each cohort. Pharmacodynamic results suggest the immunomodulatory action of daratumumab contributes to a conducive environment for talquetamab by reducing immunosuppressive cells. Talquetamab plus daratumumab demonstrated promising efficacy outcomes in patients with heavily pretreated disease, with a safety profile consistent with each agent as monotherapy. This trial was registered at www.clinicaltrials.gov as #NCT04108195.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Chari A, van de Donk NWCJ, Dholaria B, et al. Talquetamab plus daratumumab for the treatment of relapsed or refractory multiple myeloma in the TRIMM-2 study. Blood. 2025. PMID: 40983036. doi:10.1182/blood.2025029360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。